Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.

@article{Switzer2011NitricOA,
  title={Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.},
  author={Christopher H. Switzer and Sharon A Glynn and Lisa A. Ridnour and Robert Y. S. Cheng and Michael P Vitek and Stefan Ambs and David A Wink},
  journal={Trends in pharmacological sciences},
  year={2011},
  volume={32 11},
  pages={644-51}
}
Basal-like breast cancer is an aggressive disease with limited therapeutic options because these tumors frequently express the 'triple-negative' phenotype. We have recently reported that inducible nitric oxide synthase (NOS2) is a strong predictor of survival in patients with estrogen receptor negative [ER(-)] breast cancer, and that NOS2 expression is correlated with a basal-like phenotype. Recent reports also describe the pro-tumor effects of NO in breast and many other types of cancer. NO… CONTINUE READING